Does the media refer more to LMAT or GKOS?

In the previous week, Glaukos had 26 more articles in the media than LeMaitre Vascular. MarketBeat recorded 32 mentions for Glaukos and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat Glaukos' score of 0.72 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 11 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LQDA or LMAT?

LeMaitre Vascular has lower revenue, but higher earnings than Liquidia. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $288.07M 25.79 -$68.92M $0.14 596.64 LeMaitre Vascular $249.60M 9.44 $57.73M $2.71 38.04

Does the media prefer LQDA or LMAT?

In the previous week, Liquidia had 15 more articles in the media than LeMaitre Vascular. MarketBeat recorded 21 mentions for Liquidia and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat Liquidia's score of 0.69 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer LMAT or STVN?

LeMaitre Vascular presently has a consensus price target of $112.60, indicating a potential upside of 9.22%. Given LeMaitre Vascular's higher possible upside, equities research analysts clearly believe LeMaitre Vascular is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LeMaitre Vascular 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media favor LMAT or STVN?

In the previous week, LeMaitre Vascular had 4 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for LeMaitre Vascular and 2 mentions for Stevanato Group. LeMaitre Vascular's average media sentiment score of 0.76 beat Stevanato Group's score of 0.54 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLCO or LMAT?

In the previous week, Bausch + Lomb had 12 more articles in the media than LeMaitre Vascular. MarketBeat recorded 18 mentions for Bausch + Lomb and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat Bausch + Lomb's score of 0.31 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LMAT or MMED?

In the previous week, MiniMed Group had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 8 mentions for MiniMed Group and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat MiniMed Group's score of 0.20 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

LeMaitre Vascular (LMAT) Competitors

$103.09 +1.77 (+1.75%)

As of 11:39 AM Eastern

Compare

LMAT vs. GKOS, LQDA, STVN, BLCO, and MMED

Should you buy LeMaitre Vascular stock or one of its competitors? MarketBeat compares LeMaitre Vascular with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LeMaitre Vascular include Glaukos (GKOS), Liquidia (LQDA), Stevanato Group (STVN), Bausch + Lomb (BLCO), and MiniMed Group (MMED).

How does LeMaitre Vascular compare to Glaukos?

LeMaitre Vascular (NASDAQ:LMAT) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

LeMaitre Vascular has a net margin of 24.35% compared to Glaukos' net margin of -30.68%. LeMaitre Vascular's return on equity of 15.36% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Glaukos	-30.68%	-6.37%	-4.78%

LeMaitre Vascular presently has a consensus target price of $112.60, suggesting a potential upside of 9.22%. Glaukos has a consensus target price of $177.33, suggesting a potential upside of 3.23%. Given LeMaitre Vascular's higher possible upside, equities research analysts plainly believe LeMaitre Vascular is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

LeMaitre Vascular has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Glaukos had 26 more articles in the media than LeMaitre Vascular. MarketBeat recorded 32 mentions for Glaukos and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat Glaukos' score of 0.72 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	11 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.44	$57.73M	$2.71	38.04
Glaukos	$507.44M	19.97	-$187.69M	-$3.25	N/A

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 5.9% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

LeMaitre Vascular beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Liquidia?

Liquidia (NASDAQ:LQDA) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

LeMaitre Vascular has a net margin of 24.35% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
LeMaitre Vascular	24.35%	15.36%	9.78%

Liquidia currently has a consensus target price of $86.18, suggesting a potential upside of 3.18%. LeMaitre Vascular has a consensus target price of $112.60, suggesting a potential upside of 9.22%. Given LeMaitre Vascular's higher possible upside, analysts clearly believe LeMaitre Vascular is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Liquidia has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

LeMaitre Vascular has lower revenue, but higher earnings than Liquidia. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$288.07M	25.79	-$68.92M	$0.14	596.64
LeMaitre Vascular	$249.60M	9.44	$57.73M	$2.71	38.04

In the previous week, Liquidia had 15 more articles in the media than LeMaitre Vascular. MarketBeat recorded 21 mentions for Liquidia and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat Liquidia's score of 0.69 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Liquidia beats LeMaitre Vascular on 9 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Stevanato Group?

LeMaitre Vascular (NASDAQ:LMAT) and Stevanato Group (NYSE:STVN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, LeMaitre Vascular had 4 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for LeMaitre Vascular and 2 mentions for Stevanato Group. LeMaitre Vascular's average media sentiment score of 0.76 beat Stevanato Group's score of 0.54 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular presently has a consensus price target of $112.60, indicating a potential upside of 9.22%. Given LeMaitre Vascular's higher possible upside, equities research analysts clearly believe LeMaitre Vascular is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

LeMaitre Vascular has a net margin of 24.35% compared to Stevanato Group's net margin of 11.76%. LeMaitre Vascular's return on equity of 15.36% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Stevanato Group	11.76%	10.27%	6.08%

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LeMaitre Vascular has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Stevanato Group has higher revenue and earnings than LeMaitre Vascular. Stevanato Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.44	$57.73M	$2.71	38.04
Stevanato Group	€1.34B	4.54	€158.21M	€0.59	34.06

Summary

LeMaitre Vascular beats Stevanato Group on 12 of the 17 factors compared between the two stocks.

How does LeMaitre Vascular compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

LeMaitre Vascular has a net margin of 24.35% compared to Bausch + Lomb's net margin of -3.21%. LeMaitre Vascular's return on equity of 15.36% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
LeMaitre Vascular	24.35%	15.36%	9.78%

Bausch + Lomb presently has a consensus price target of $18.75, suggesting a potential upside of 12.36%. LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 9.22%. Given Bausch + Lomb's higher probable upside, equities analysts clearly believe Bausch + Lomb is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

LeMaitre Vascular has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.32B	1.12	-$360M	-$0.48	N/A
LeMaitre Vascular	$249.60M	9.44	$57.73M	$2.71	38.04

In the previous week, Bausch + Lomb had 12 more articles in the media than LeMaitre Vascular. MarketBeat recorded 18 mentions for Bausch + Lomb and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat Bausch + Lomb's score of 0.31 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch + Lomb has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Summary

LeMaitre Vascular beats Bausch + Lomb on 11 of the 15 factors compared between the two stocks.

How does LeMaitre Vascular compare to MiniMed Group?

LeMaitre Vascular (NASDAQ:LMAT) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, MiniMed Group had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 8 mentions for MiniMed Group and 6 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.76 beat MiniMed Group's score of 0.20 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.44	$57.73M	$2.71	38.04
MiniMed Group	$3.10B	1.70	-$190.97M	-$0.68	N/A

LeMaitre Vascular has a net margin of 24.35% compared to MiniMed Group's net margin of 0.00%. LeMaitre Vascular's return on equity of 15.36% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
MiniMed Group	N/A	N/A	N/A

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Comparatively, 2.2% of MiniMed Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LeMaitre Vascular presently has a consensus target price of $112.60, suggesting a potential upside of 9.22%. MiniMed Group has a consensus target price of $21.62, suggesting a potential upside of 15.12%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts plainly believe MiniMed Group is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

LeMaitre Vascular beats MiniMed Group on 10 of the 15 factors compared between the two stocks.

Get LeMaitre Vascular News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMAT vs. The Competition

Export

Metric	LeMaitre Vascular	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.36B	$5.68B	$6.79B	$12.63B
Dividend Yield	0.99%	1.79%	2.59%	10.03%
P/E Ratio	38.04	23.65	282.14	25.05
Price / Sales	9.44	58.64	573.43	80.07
Price / Cash	34.91	32.53	28.60	46.71
Price / Book	5.94	6.44	11.09	6.19
Net Income	$57.73M	$151.15M	$3.49B	$347.61M
7 Day Performance	4.20%	2.72%	0.42%	0.74%
1 Month Performance	0.20%	-1.87%	-4.33%	-3.72%
1 Year Performance	27.21%	4.04%	63.09%	20.27%

LeMaitre Vascular Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMAT LeMaitre Vascular	3.8781 of 5 stars	$103.09 +1.7%	$112.60 +9.2%	+25.0%	$2.36B	$249.60M	38.04	490	Upcoming Earnings Analyst Downgrade
GKOS Glaukos	1.8392 of 5 stars	$146.52 -3.5%	$155.23 +5.9%	+92.8%	$8.61B	$507.44M	N/A	1,094	Earnings Report Analyst Upgrade
LQDA Liquidia	3.2688 of 5 stars	$83.43 -1.2%	$86.18 +3.3%	+375.7%	$7.47B	$288.07M	599.92	50
STVN Stevanato Group	2.9498 of 5 stars	€19.89 +0.5%	N/A	-20.9%	€6.02B	€1.34B	33.69	6,010	Upcoming Earnings
BLCO Bausch + Lomb	3.4174 of 5 stars	$16.44 +1.0%	$18.00 +9.5%	+24.9%	$5.86B	$5.21B	N/A	13,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMAT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, LQDA, STVN, BLCO, and MMED

How does LeMaitre Vascular compare to Glaukos?

Summary

How does LeMaitre Vascular compare to Liquidia?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Summary

How does LeMaitre Vascular compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, LQDA, STVN, BLCO, and MMED

How does LeMaitre Vascular compare to Glaukos?

Is LMAT or GKOS more profitable?

Do analysts recommend LMAT or GKOS?

Which has more volatility & risk, LMAT or GKOS?

Does the media refer more to LMAT or GKOS?

Which has preferable earnings & valuation, LMAT or GKOS?

Do institutionals & insiders hold more shares of LMAT or GKOS?

Summary

How does LeMaitre Vascular compare to Liquidia?

Is LQDA or LMAT more profitable?

Do analysts rate LQDA or LMAT?

Do institutionals and insiders have more ownership in LQDA or LMAT?

Which has more volatility & risk, LQDA or LMAT?

Which has better earnings and valuation, LQDA or LMAT?

Does the media prefer LQDA or LMAT?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Does the media favor LMAT or STVN?

Do analysts prefer LMAT or STVN?

Is LMAT or STVN more profitable?

Do insiders & institutionals believe in LMAT or STVN?

Which has more volatility & risk, LMAT or STVN?

Which has stronger earnings & valuation, LMAT or STVN?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Is BLCO or LMAT more profitable?

Do analysts prefer BLCO or LMAT?

Do insiders and institutionals believe in BLCO or LMAT?

Which has preferable earnings & valuation, BLCO or LMAT?

Does the media prefer BLCO or LMAT?

Which has more risk and volatility, BLCO or LMAT?

Summary

How does LeMaitre Vascular compare to MiniMed Group?

Does the media prefer LMAT or MMED?

Which has preferable valuation & earnings, LMAT or MMED?

Is LMAT or MMED more profitable?

Do institutionals & insiders hold more shares of LMAT or MMED?

Do analysts prefer LMAT or MMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools